Georgia Life Sciences Partners with U.S. Chamber Foundation to Bring Real-World Innovation to Georgia Classrooms

Georgia Life Sciences Partners with U.S. Chamber Foundation to Bring Real-World Innovation to Georgia Classrooms

60 + high school students tackle real industry challenges through national EPIC program


July 7, 2025

ATLANTA – Georgia Life Sciences (GLS) has successfully completed its first collaboration with the U.S. Chamber of Commerce Foundation’s Employer Provided Innovation Challenges (EPIC) program, bringing hands-on, real-world learning into Georgia classrooms and spotlighting the state’s growing leadership in workforce innovation.

 

Through this groundbreaking initiative, GLS developed and piloted three challenge-based projects designed to spark student interest in the life sciences:

  • Navigating Medical Device Regulatory Pathways
  • Innovative Solutions in Food Production
  • Automated Biomanufacturing

 

Over 60 high school students across the state formed 12 teams to tackle these challenges, working directly with industry volunteer mentors to co-design creative solutions. All participants earned credentials for their work, demonstrating not only career awareness but real-world readiness for Georgia’s growing bioscience sector.

 

One standout team—composed of homeschool students from the Georgia Black Home Educators Network (GBHEN), sponsored by Blue Heron Urban Farm and Sanctuary—was selected to present at the EPIC National Convening on June 24 in Washington, D.C., hosted at the U.S. Chamber of Commerce. The team shared their innovations in sustainable food production, highlighting the role of student ingenuity in solving global challenges.

 

“This program gave students a window into the real world of biotech, medical devices, and agtech,” said Dr. Phil Gibson, Executive Director for the Georgia Life Sciences Institute. “It also gave our industry partners a powerful new way to engage with the future workforce—and even shape it.”

 

EPIC, launched by the U.S. Chamber Foundation, is redefining the connection between business innovation and workforce development by giving students access to real problems, real collaboration, and real career exposure.

 

This effort is part of Georgia Life Sciences’ broader mission to build a sustainable talent pipeline in the life sciences—from classroom to career. Through initiatives like this partnership with the Us Chamber Foundation and the public/private partnership with Georgia’s Department of Education, the Biotech Teacher Training Initiative (BTTI), GLS provides immersive, standards-aligned professional development for Georgia educators to bring modern biotech concepts and techniques into biology, chemistry, agriculture, and environmental science classrooms statewide.

 

Why It Matters

As Georgia’s life sciences industry continues to grow, workforce demand is outpacing supply. Programs like EPIC play a vital role in bridging that gap by increasing industry awareness early in the pipeline. Building student familiarity with bioscience careers—and connecting them with real industry mentors—is essential to strengthening Georgia’s long-term competitiveness in biotechnology, biomanufacturing, and global health innovation.

 

About Georgia Life Sciences

Georgia Life Sciences is the statewide association advancing the life sciences ecosystem through policy advocacy, economic development, workforce initiatives, and industry-led innovation. From breakthrough biomanufacturing to patient access, GLS is committed to making Georgia a leader in global health and biotechnology.

By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
By Maria Thacker Goethe August 29, 2025
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “ The Future of Life Sciences Investment .” Early-stage life sciences companies are unique for their ability to leverage specialized scientific knowledge and a nimble structure to pursue new, innovative approaches to treat a disease. However, these companies often rely on external investment, such as from venture capital (VC), to be able navigate the cost pressures and considerable risks associated with early-stage drug development. Life sciences mergers and acquisitions (M&A) represent a clear exit point for VC investors, attracting investment and allowing companies of all sizes to combine their complementary resources, skills and expertise to bring new medicines to patients. Amidst an increasingly challenging investment landscape, preserving M&A is critical to continue supporting the hundreds of pre-clinical companies working to bring new therapies to patients. Highlights from the blog are included below: “Over the past decade, the biopharmaceutical industry has quietly produced a steady drumbeat of significant medical advances…Despite these advances, there’s global pressure to innovate faster. While the U.S. has historically been the global leader in scientific research and development, it now faces increased international competition…” “For America to maintain its competitive advantage, it must continue investing in research and clinical development… We believe that venture capital can meaningfully contribute to fill this investment gap, providing support for America’s continued ability to innovate and advance global human health." “This isn’t just our belief — venture-backed companies are driving enhanced R&D productivity and efficiency. Recent data shows that roughly 65% of new medicines originated from outside of large pharmaceutical companies.” “We believe the most meaningful breakthroughs in life sciences are rarely achieved in isolation. They’re the result of deep, sustained collaboration — between scientists and clinicians, industry and academia, and increasingly, founders and investors.” As this blog highlights, life sciences M&A remains a critical pathway for fueling investment and supporting America’s role as a global leader in life sciences innovation. Policymakers must recognize the value of life science M&A and support enforcement policies that encourage these pro-competitive partnerships and the innovative medicines they bring to patients. About the Partnership for U.S. Life Science Ecosystem (PULSE) The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. PULSE is dedicated to raising awareness about the unique life sciences ecosystem and the importance of M&A in leveraging efficiency and experience across companies of all sizes. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that advances next generation treatments and cures for patients. For more information, visit https://pulseforinnovation.org/.
MORE POSTS